Literature DB >> 32714517

Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics.

Lynn E Taylor1,2,3.   

Abstract

Watch an interview with the author.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2020        PMID： 32714517      PMCID： PMC7373770          DOI： 10.1002/cld.921

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  30 in total

1.  Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston.

Authors:  Marguerite E Beiser; Kamala Smith; Molly Ingemi; Emma Mulligan; Travis P Baggett
Journal:  Int J Drug Policy       Date:  2019-04-06

2.  Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment.

Authors:  Steven L Batki; Kelly M Canfield; Robert Ploutz-Snyder
Journal:  Am J Addict       Date:  2011-05-31

Review 3.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Authors:  Philip Bruggmann; Alain H Litwin
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

4.  Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents.

Authors:  J Grebely; J D Raffa; C Lai; T Kerr; B Fischer; M Krajden; G J Dore; M W Tyndall
Journal:  J Viral Hepat       Date:  2011-01       Impact factor: 3.728

5.  Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study.

Authors:  Steven L Batki; Kelly M Canfield; Emily Smyth; Robert Ploutz-Snyder; Robert A Levine
Journal:  J Addict Dis       Date:  2010-07

6.  Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.

Authors:  Nathalie Scherz; Philip Bruggmann; Nathalie Brunner
Journal:  Int J Drug Policy       Date:  2018-10-24

7.  Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.

Authors:  Jenny Iversen; Gregory J Dore; Beth Catlett; Philip Cunningham; Jason Grebely; Lisa Maher
Journal:  J Hepatol       Date:  2018-10-25       Impact factor: 25.083

8.  Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility.

Authors:  Natasha K Martin; Peter Vickerman; Graham R Foster; Sharon J Hutchinson; David J Goldberg; Matthew Hickman
Journal:  J Hepatol       Date:  2011-02-12       Impact factor: 25.083

9.  Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users.

Authors:  Seyed Moayed Alavian; Alireza Mirahmadizadeh; Mehdi Javanbakht; Ali Keshtkaran; Alireza Heidari; Atefeh Mashayekhi; Shima Salimi; Mohammad Hadian
Journal:  Hepat Mon       Date:  2013-08-17       Impact factor: 0.660

10.  Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.

Authors:  Lucy Platt; Silvia Minozzi; Jennifer Reed; Peter Vickerman; Holly Hagan; Clare French; Ashly Jordan; Louisa Degenhardt; Vivian Hope; Sharon Hutchinson; Lisa Maher; Norah Palmateer; Avril Taylor; Julie Bruneau; Matthew Hickman
Journal:  Addiction       Date:  2017-10-23       Impact factor: 6.526
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.